Events & Presentations
Happening This Week
AASLD The Liver Meeting® 2019
Boston, MA – November 11, 2019 1:30pm – Slides – “Managing Cardiovascular Risk in NAFLD/NASH” – Seth Baum, M.D., Immediate Past President, American Society for Preventive Cardiology
AASLD The Liver Meeting® 2019
Boston, MA – November 11, 2019 5:30pm – Slides – “Effects of Resmetirom (MGL-3196) on Hepatic Fat, Lipids, Liver Enzymes and Markers of Liver Fibrosis in an Open-Label 36-Week Extension Study in NASH Patients” – Stephen Harrison, M.D., Medical Director for Pinnacle Clinical Research, San Antonio, Texas, and Visiting Professor of Hepatology, Oxford University
AASLD The Liver Meeting® 2019
Boston, MA – November 11, 2019 8:00am – Poster – Steatosis and Fibrosis Measured as Continuous Variables on Paired, Serial Liver Biopsies in the Resmetirom (MGL-3196) 36-Week Phase 2 NASH Study.
Upcoming & Recent Events
Evercore ISI 2nd Annual HEALTHCONx Conference
Boston, MA – December 3-5, 2019
Stifel Healthcare Conference
New York, NY – November 19-20, 2019
Wolfe Healthcare Conference
New York, NY – November 6, 2019
H.C. Wainwright 3rd Annual NASH Investor Conference
New York, NY – October 21, 2019 – Webcast – Slides
H.C. Wainwright 21st Annual Global Investment Conference
New York, NY – September 8-10 2019 – Webcast – Slides
European Society of Cardiology(ESC)
Paris, France – Saturday 31 August - Wednesday 4 September 2019 – Poster – In a 36-Week Placebo Controlled Phase 2 Trial in Patients with Non-alcoholic Steatohepatitis (NASH), Treatment with MGL-3196 (resmetirom) Significantly Reduces Atherogenic Lipoprotein Particles.
Presentations
Non-Confidential Company Presentation
LDL cholesterol, apolipoprotein B, lipoprotein(a), apolipoprotein CIII and triglyceride lowering by MGL-3196, a thyroid hormone receptor beta selective agonist, in a 12 week study in HeFH patients
August 21, 2018
MGL-3196, a β-Selective Thyroid Hormone Receptor (THR) Agonist, Demonstrates Metabolic, Anti-inflammatory and Anti-fibrotic Benefits in a Long-term High Fat Diet (HFD) Mouse NASH Model
October 20-24, 2017
MRI-PDFF response in MGL-3196 and placebo treated patients predicts reduction in ballooning and inflammation components of NAS and NASH resolution in a 36-week serial liver biopsy study
Archived Events
5th Paris NASH meeting
Paris, France – July 11, 2019
JMP Securities Life Sciences Conference
New York, NY – June 19 – 20, 2019
Goldman Sachs 40th Annual Global Healthcare Conference
Rancho Palos Verdes, CA – June 11 - 13, 2019
Jefferies 2019 Global Healthcare Conference
New York, NY – June 4 - 7
UBS 2019 Global Healthcare Conference
New York, NY – May 20 – 22, 2019
3rd Annual NASH Summit
Boston, MA – April 22-25 2019
International Liver Congress™ 2019, European Association for the Study of the Liver (EASL)
Vienna – April 11, 2019
Roth NASH Investor Conference
New York, NY – March 28, 2019
More Archived Events …
Oppenheimer Healthcare Conference
New York, NY – March 19 – 20, 2019
Roth Conference
Laguna Niguel, CA – March 17 – 19, 2019
Cowen Healthcare Conference
Boston, MA – March 11 – 13, 2019
NASH-TAG 2019 Conference
Park City, UT – January 3 – 5, 2019
Citi Global Healthcare Conference
New York, NY – December 5–6, 2018
3rd Annual World Preclinical Congress
Lisbon, Portugal – November 27–30, 2018
Evercore ISI 2018 HealthConX Conference
Boston, MA – November 27, 2018
Evercore ISI Madrigal
Webinar – November 19, 2018
Credit Suisse Annual Healthcare Conference
Scottsdale, AZ – November 14, 2018
AASLD – The Liver Meeting 2018 – Analyst/Investor KOL Event
San Francisco, CA – November 12, 2018
AASLD – The Liver Meeting 2018 – Plenary Presentation
San Francisco, CA – November 12, 2018
NASH Summit Europe 2018
Frankfurt, Germany – October 22–24, 2018
Roth NASH Investor Conference
New York, NY – October 17, 2018
H. C. Wainwright 20th Annual Global Investment Conference
New York, NY – September 4-6, 2018
JMP Securities Life Sciences Conference
New York, NY – June 21, 2018
Goldman Sachs 39th Annual Global Healthcare Conference
Rancho Palos Verdes, California – June 13, 2018
Review of Madrigal’s 36-week phase 2 results for MGL-3196
New York, NY – May 31, 2018 8:30am
EASL International Liver Congress 2018
Paris, France – April 11-15, 2018
HC Wainwright NASH Investor Conference 2018
New York, NY – March 19, 2018
The Cowen and Company 38th Annual Health Care Conference
Boston, MA – March 14th 2018
Global NASH Congress
London, UK – February 26-27, 2018
Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)
Conference Call & Webcast – February 8th, 2018
2018 NASH-TAG CONFERENCE
Thyroid Hormone Receptor Agonist – Becky Taub, MD
Park City, Utah – January 4-6, 2018
Madrigal Announces Top-line Results from Phase 2 NASH Clinical Trial
Conference Call & Webcast – December 6 2017 8:30 am ET
Evercore ISI Biopharma Catalyst/Deep Dive Conference
Boston, MA – November 29-30, 2017
Jefferies 2017 London Healthcare Conference
London, UK – November 15-16, 2017
FIRST EASL NAFLD SUMMIT
Vitamin D, thyroid function (the obvious and neglected; including Liver-Directed Thyroid Hormone Receptor-β (THR-β) agonists
Rome, Italy – November 9-11, 2017
AASLD Liver Meeting
Poster # 1969: MGL-3196, a β-Selective Thyroid Hormone Receptor (THR) Agonist, Demonstrates Metabolic, Anti-inflammatory and Anti-fibrotic Benefits in a Long-term High Fat Diet (HFD) Mouse NASH Model
Washington, DC – October 20-24, 2017
Discovery on Target Conference:
Thyroid Hormone Receptor Targets
Boston, MA – September 26, 2017
Cantor Fitzgerald Healthcare Conference
New York, NY – September 25-27, 2017
HC Wainwright / Rodman & Renshaw Annual Healthcare Conference
New York, NY – September 10-12, 2017
JMP Securities Life Sciences Conference
New York, NY – June 20-21, 2017
Jefferies 2017 Healthcare Conference
New York, NY – June 6-9, 2017
Jefferies 2018 Global Healthcare Conference
New York, NY – June 5-8, 2018
H.C. Wainwright NASH Investor Conference
New York, NY – April 3, 2017
ROTH Investor Conference
Laguna Niguel, CA – March 13, 2017
Cowen Healthcare Conference
Boston, MA – March 8, 2017
